Modular Medical Launches New Website for Pivot Tubeless Insulin Patch Pump
Rhea-AI Summary
Modular Medical (NASDAQ:MODD) launched PivotPump.com, a patient-focused site for its Pivot tubeless insulin patch pump. The site supports people exploring insulin pump therapy.
Pivot received FDA clearance in April 2026, with initial patients expected June 2026 and a commercial launch targeted for fall 2026.
Positive
- Pivot insulin delivery system received FDA clearance in April 2026
- Initial Pivot patients expected to begin using the system in June 2026
- Commercial launch of Pivot targeted for fall 2026
- Launch of PivotPump.com to educate and support pump therapy adoption
- Design targets patients underserved by traditional insulin pump solutions
Negative
- None.
News Market Reaction – MODD
In the Jun 4 session, MODD gained 6.40%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Investor webinar | Neutral | -3.3% | Announcement of CEO-led investor webinar on FDA wins and manufacturing. |
| Apr 19 | Equity offering | Negative | -7.7% | Registered direct stock offering at $4.50 per share for ~$3.4M. |
| Apr 16 | Nasdaq compliance | Positive | +3.0% | Regained compliance with Nasdaq $1.00 minimum bid requirement. |
| Apr 09 | FDA clearance | Positive | -1.6% | Received FDA 510(k) clearance for Pivot tubeless insulin patch pump. |
| Mar 26 | Reverse split | Negative | -9.8% | 1-for-30 reverse stock split to meet Nasdaq bid-price rules. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent material events, including financings and a reverse split, mostly saw price declines, while only the Nasdaq compliance update aligned positively with a gain.
Over the past few months, Modular Medical has combined balance-sheet moves with regulatory and listing milestones. A 1-for-30 reverse split on Mar 31, 2026 and subsequent registered offerings, including 750,000 shares at $4.50, strengthened capital access but drew negative price reactions. In contrast, regaining Nasdaq minimum bid compliance on Apr 14, 2026 was followed by a positive move. The Apr 9, 2026 FDA 510(k) clearance for Pivot drew a modest decline, suggesting the market has not consistently rewarded positive operational milestones.
Key Terms
u.s. food and drug administration regulatory
fda clearance regulatory
insulin pump therapy medical
tubeless insulin patch pump medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial patients expected in June 2026
SAN DIEGO, CA / ACCESS Newswire / June 4, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy.
This launch follows the Company's receipt of U.S. Food and Drug Administration ("FDA") clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical's strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026.
Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction.
The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company's focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.
Modular Medical continues to focus on removing barriers to the adoption of insulin pumps through simplified onboarding, intuitive design, and an improved user experience, with the goal of enabling broader transition from multiple daily injections to pump therapy.
For more information on the Pivot system, visit the dedicated site: PivotPump.com and the newly launched YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product; whether the Company will have initial users by June 30, 2026; the timing of the commercial launch of the Pivot product; whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire